T1	intervention 14 25	fulvestrant
T2	control 33 42	tamoxifen
T4	intervention-participants 812 815	313
T5	control-participants 862 865	274
T7	outcome 1121 1140	time to progression
T8	iv-cont-median 1159 1169	6.8 months
T9	cv-cont-median 1174 1184	8.3 months
T12	outcome 1363 1373	median TTP
T14	iv-cont-median 1378 1388	8.2 months
T15	cv-cont-median 1409 1419	8.3 months
T18	outcome 1490 1513	objective response rate
T19	iv-bin-percent 1545 1550	31.6%
T20	cv-bin-percent 1572 1577	33.9%
T22	iv-bin-percent 1598 1603	33.2%
T23	cv-bin-percent 1608 1613	31.1%
T3	eligibility 605 702	patients with metastatic/locally advanced breast cancer previously untreated for advanced disease
T10	outcome 1699 1713	well tolerated
